CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Thousands |
3 Months Ended |
6 Months Ended |
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS |
|
|
|
|
| SUBLICENSE REVENUE |
$ 0
|
$ 2,000
|
$ 0
|
$ 2,000
|
| OPERATING EXPENSES: |
|
|
|
|
| Sublicense transaction costs |
0
|
254
|
0
|
254
|
| General and administrative |
178
|
84
|
366
|
313
|
| Research and development |
427
|
322
|
1,028
|
623
|
| Total operating expenses |
605
|
660
|
1,394
|
1,190
|
| Income (loss) after operating expenses |
(605)
|
1,340
|
(1,394)
|
810
|
| Interest and other income (expense), net |
(63)
|
(62)
|
(126)
|
(122)
|
| Income (loss) from operations before taxes |
(668)
|
1,278
|
(1,520)
|
688
|
| Income tax benefit (expense) |
0
|
0
|
(3)
|
3
|
| NET INCOME (LOSS) |
(668)
|
1,278
|
(1,523)
|
691
|
| Less: Net Income (Loss) attributable to the noncontrolling interest |
0
|
0
|
0
|
0
|
| Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders |
$ (668)
|
$ 1,278
|
$ (1,523)
|
$ 691
|
| Per Share Information: |
|
|
|
|
| Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders |
$ (0.01)
|
$ 0.02
|
$ (0.03)
|
$ 0.01
|
| Basic and diluted shares outstanding |
54,385
|
54,385
|
54,385
|
54,385
|